Aurobindo Pharma Limited has announced the incorporation of a new wholly owned subsidiary in Chile, marking another step in its global expansion strategy. The new entity, Aurobindo Pharma Chile SpA, has been established under its Netherlands-based subsidiary Helix Healthcare B.V., according to a filing with the stock exchanges under Regulation 30 of SEBI (LODR) Regulations, 2015.
The newly incorporated subsidiary aims to expand Aurobindo’s pharmaceutical products business in Chile, tapping into the growing Latin American healthcare market. The incorporation was completed on October 7, 2025, with official formation documents received on October 22, 2025.
The initial capital investment in Aurobindo Pharma Chile SpA stands at CLP 1,000,000 (approximately USD 1,050), divided into 100 shares of CLP 10,000 each, subscribed entirely in cash. The subsidiary is 100% owned by Helix Healthcare B.V., which in turn is a wholly owned arm of Aurobindo Pharma Limited.
The company stated that the move aligns with its goal of deepening its presence in emerging pharmaceutical markets. No governmental or regulatory approvals were required for the incorporation, as it falls within Aurobindo’s existing operational domain in pharmaceuticals.
With this addition, Aurobindo Pharma continues to expand its international network, reinforcing its commitment to reaching newer geographies and strengthening its supply chain in key markets across Latin America.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
